Cover Image
市場調查報告書

骨關節炎疼痛:開發中產品分析

Osteoarthritis Pain - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232825
出版日期 內容資訊 英文 224 Pages
訂單完成後即時交付
價格
Back to Top
骨關節炎疼痛:開發中產品分析 Osteoarthritis Pain - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 224 Pages
簡介

骨關節炎疼痛,是隨著軟骨的損傷而發病的伴隨骨關節炎最常見的症狀。

本報告提供骨關節炎止痛藥開發平台現狀及最新更新的各開發階段比較分析,提供您包含最新新聞和發表之企業和研究機關開發中治療藥,治療藥評估及中止的計劃等相關資訊。

簡介

  • 調查範圍

骨關節炎疼痛概要

治療藥的開發

  • 開發中產品的概要
  • 骨關節炎疼痛:企業開發中的治療藥
  • 骨關節炎疼痛:大學/機關研究中的治療藥
  • 骨關節炎疼痛:企業開發中的產品
  • 骨關節炎疼痛:大學/機關研究中的產品

骨關節炎疼痛:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

骨關節炎疼痛的開發治療藥的企業

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Allergan Plc
  • Ampio Pharmaceuticals Inc
  • Antibe Therapeutics Inc
  • Aralez Pharmaceuticals Inc
  • Arena Pharmaceuticals Inc
  • Array BioPharma Inc
  • Astellas Pharma Inc.
  • Axsome Therapeutics Inc
  • BELLUS Health Inc
  • Boehringer Ingelheim GmbH
  • Cara Therapeutics Inc
  • Chromocell Corp
  • Eli Lilly and Company
  • Elite Pharmaceuticals Inc
  • Eupraxia Pharmaceuticals Inc
  • Flexion Therapeutics Inc
  • Genzyme Corp
  • GlaxoSmithKline Plc
  • Grunenthal GmbH
  • Iroko Pharmaceuticals LLC
  • Marina Biotech Inc
  • Medestea Research & Production SpA
  • MedImmune LLC
  • Merck & Co Inc
  • Nuvo Pharmaceuticals Inc
  • 小野藥品工業
  • Pfizer Inc
  • Phosphagenics Ltd
  • ProteoThera Inc
  • pSivida Corp
  • Purdue Pharma LP
  • Regeneron Pharmaceuticals Inc
  • Rottapharm Biotech Srl
  • Shionogi & Co Ltd
  • Symic Biomedical Inc
  • Taiwan Liposome Company Ltd
  • Vertex Pharmaceuticals Inc
  • Zynerba Pharmaceuticals Inc

藥物簡介

骨關節炎疼痛:暫停中的計劃

骨關節炎疼痛:開發中止的產品

骨關節炎疼痛:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9784IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2017, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 23, 9, 1, 23, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Osteoarthritis Pain - Overview
  • Osteoarthritis Pain - Therapeutics Development
  • Osteoarthritis Pain - Therapeutics Assessment
  • Osteoarthritis Pain - Companies Involved in Therapeutics Development
  • Osteoarthritis Pain - Drug Profiles
  • Osteoarthritis Pain - Dormant Projects
  • Osteoarthritis Pain - Discontinued Products
  • Osteoarthritis Pain - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Osteoarthritis Pain, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Osteoarthritis Pain - Pipeline by AbbVie Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Achelios Therapeutics Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Osteoarthritis Pain - Pipeline by Allergan Plc, H2 2017
  • Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Antibe Therapeutics Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Array BioPharma Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Astellas Pharma Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by BELLUS Health Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Osteoarthritis Pain - Pipeline by Cara Therapeutics Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Centrexion Therapeutics Corp, H2 2017
  • Osteoarthritis Pain - Pipeline by Chromocell Corp, H2 2017
  • Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Osteoarthritis Pain - Pipeline by Flexion Therapeutics Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Genzyme Corp, H2 2017
  • Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H2 2017
  • Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals LLC, H2 2017
  • Osteoarthritis Pain - Pipeline by Marina Biotech Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Medestea Research & Production SpA, H2 2017
  • Osteoarthritis Pain - Pipeline by MedImmune LLC, H2 2017
  • Osteoarthritis Pain - Pipeline by Merck & Co Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • Osteoarthritis Pain - Pipeline by Pfizer Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by ProteoThera Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by pSivida Corp, H2 2017
  • Osteoarthritis Pain - Pipeline by RaQualia Pharma Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Rottapharm Biotech Srl, H2 2017
  • Osteoarthritis Pain - Pipeline by Shionogi & Co Ltd, H2 2017
  • Osteoarthritis Pain - Pipeline by Symic Biomedical Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Taiwan Liposome Company Ltd, H2 2017
  • Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Inc, H2 2017
  • Osteoarthritis Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
  • Osteoarthritis Pain - Dormant Projects, H2 2017
  • Osteoarthritis Pain - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Osteoarthritis Pain - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Osteoarthritis Pain - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Osteoarthritis Pain - Discontinued Products, H2 2017
  • Osteoarthritis Pain - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Osteoarthritis Pain, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top